Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the release of abstracts on alisertib to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting will be held at McCormick Place in Chicago and online from May 31-June 4.

Full abstracts of the following posters are available online at https://conferences.asco.org/am/abstracts.

• Abstract 1037: Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC 041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC)
  Presenter: Karthik Giridhar, MD., Mayo Clinic

• Abstract 8572: Phase I/Ib study of the aurora kinase A Inhibitor alisertib in combination with osimertinib in advanced osimertinib-resistant EGFR-mutated lung cancer
  Presenter: Turja Chakrabarti, MD., University of California, San Francisco#modernbusinessnetwork#modernusinessindia#modernaviationtimes #modernbusinessamerica #modernbusinesseurope#modernautomobileindia #modernbusinessasia#modernbusinessgulf#modernagriculturetimes #modernbusinessgerman#modernbusinessworld#modernbusinesstimes #modernbusinessindiamagazine#magazine